These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9850031

  • 1. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
    Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D.
    J Clin Oncol; 1998 Dec; 16(12):3858-65. PubMed ID: 9850031
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
    Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP.
    J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T.
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [Abstract] [Full Text] [Related]

  • 6. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.
    Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
    [Abstract] [Full Text] [Related]

  • 7. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
    Murren JR, Peccerillo K, DiStasio SA, Li X, Leffert JJ, Pizzorno G, Burtness BA, McKeon A, Cheng Y.
    Cancer Chemother Pharmacol; 2000 Nov; 46(1):43-50. PubMed ID: 10912577
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A.
    Cancer Res; 1994 May 15; 54(10):2636-42. PubMed ID: 8168091
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T.
    J Clin Oncol; 1994 Jan 15; 12(1):90-6. PubMed ID: 7505810
    [Abstract] [Full Text] [Related]

  • 10. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
    Jefford M, Michael M, Rosenthal MA, Davis ID, Green M, McClure B, Smith J, Waite B, Zalcberg J.
    Invest New Drugs; 2004 Apr 15; 22(2):185-92. PubMed ID: 14739668
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
    de Jonge MJ, Sparreboom A, Planting AS, van der Burg ME, de Boer-Dennert MM, ter Steeg J, Jacques C, Verweij J.
    J Clin Oncol; 2000 Jan 15; 18(1):187-94. PubMed ID: 10623709
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS.
    Clin Lung Cancer; 2003 Jul 15; 5(1):40-5. PubMed ID: 14596703
    [Abstract] [Full Text] [Related]

  • 13. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG, Pendyala L, Smith PF, Creaven PJ, Reid ME, Badmaev V, Azrak RG, Prey JD, Lawrence D, Rustum YM.
    Clin Cancer Res; 2006 Feb 15; 12(4):1237-44. PubMed ID: 16489079
    [Abstract] [Full Text] [Related]

  • 14. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL.
    Clin Cancer Res; 2000 Jun 15; 6(6):2236-44. PubMed ID: 10873073
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.
    Nakanishi Y, Takayama K, Wataya H, Izumi M, Minami T, Takano K, Inoue K, Osaki S, Kimotsuki K, Harada T, Hara N.
    Chemotherapy; 2002 Sep 15; 48(4):205-10. PubMed ID: 12218268
    [Abstract] [Full Text] [Related]

  • 18. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
    Koizumi W, Kurihara M, Satoh A, Takiuchi H, Tanabe S, Shimada K, Iwasaki R, Saigenji K.
    Anticancer Res; 2005 Sep 15; 25(2B):1257-62. PubMed ID: 15865075
    [Abstract] [Full Text] [Related]

  • 19. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
    Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S.
    J Clin Oncol; 1997 Mar 15; 15(3):921-7. PubMed ID: 9060529
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
    Langer CJ, Somer R, Litwin S, Feigenberg S, Movsas B, Maiale C, Sherman E, Millenson M, Nicoloau N, Huang C, Treat J.
    J Thorac Oncol; 2007 Mar 15; 2(3):203-9. PubMed ID: 17410043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.